Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
RESEARCH TOOLSreports
Holding XERS?
Track your performance easily
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Aug 10, 2022
|% Change Since: -4.76%
|Next Earnings Date:May 11, 2022
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance with record-breaking revenue growth driven by Recorlev and Gvoke, despite some challenges such as pricing pressure on Keveyis and a manufacturing write-off. The overall sentiment is positive due to the significant achievements and strong financial position.Company Guidance
During the Xeris Biopharma Q3 2024 earnings call, the company provided strong guidance, raising their revenue expectations to $198 million to $202 million for the year. This comes on the back of a record-breaking quarter with total revenue exceeding $54 million, driven by a 27% growth in product revenue, marking the 12th consecutive quarter of over 20% growth. Notably, Recorlev revenue nearly doubled year-over-year to $18 million, while Gvoke revenue increased by 29% to almost $23 million. The company also reported a healthy cash position of over $69 million, allowing continued strategic growth investments without needing dilutive financing. Looking ahead, Xeris is focused on advancing its XP-8121 pipeline and maintaining robust growth across its product lines, with plans for more detailed 2025 guidance to be shared in March.Record-Breaking Revenue and Growth
Total revenue exceeded $54 million with a 27% product revenue growth, marking the 12th consecutive quarter of over 20% growth. Revenue guidance was raised to $198 million to $202 million.
Recorlev Revenue Surge
Recorlev revenue increased by 119% year-over-year to nearly $18 million, with a 33% increase over the last quarter, driven by a 126% increase in new patient starts.
Gvoke Market Expansion
Gvoke achieved almost $23 million in revenue, a 29% increase, with a new prescription share of 37% and patent protection until 2036.
Strong Financial Position
The company maintained a healthy cash position with over $69 million, with no need for dilutive financing.
---
XERS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XERS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 08, 2024 | $3.36 | $3.47 | +3.27% |
| Aug 08, 2024 | $2.13 | $2.23 | +4.69% |
| May 09, 2024 | $1.85 | $1.88 | +1.62% |
| Mar 06, 2024 | $3.08 | $2.48 | -19.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Xeris Pharmaceuticals (XERS) report earnings?
Xeris Pharmaceuticals (XERS) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Xeris Pharmaceuticals (XERS) earnings time?
Xeris Pharmaceuticals (XERS) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XERS EPS forecast?
XERS EPS forecast for the fiscal quarter 2024 (Q4) is -0.06.
---